Taran I. V., Voloshchuk N. I., Grebeniuk D. I., Lozinska M. S., Nazarchuk O. A.

CLINICAL AND EXPERIMENTAL MEDICINE

Scentific article

Abstract. The widespread use of antibiotics and the associated antibiotic resistance has led to the search for ways to modulate their effects. One such endogenous modulator is hydrogen sulfide. The aim of the study was to evaluate changes in clindamycin toxicity under normal and elevated levels of hydrogen sulfide in the body. The experimental study was performed on 104 adult white female rats that were divided into groups: group 1 (control); group 2 (clindamycin intravaginally); group 3 (clindamycin intravaginally on the background of excess background hydrogen sulfide); group 4 (clindamycin orally); group 5 (clindamycin orally on the background of excess background hydrogen sulfide). Acute toxicity of tested substances and their combinations was determined by the express method of T.V. Pastushenko. In addition, the internal organs were weighed and their mass coefficients were determined. The results of the study showed no toxic effects of clindamycin phosphate in groups 2 and 3. In contrast, in group 4 animals, the initial signs of toxic effects were observed at a dose of 1510 mg/kg. In group 5, this figure was 1910 mg/kg (higher by 23.1% compared with group 4). It was found that a single administration of the maximum possible dose of antibiotic intravaginally leads to minor changes in the mass ratio of internal organs, regardless of the background level of hydrogen sulfide. When administered orally, we recorded an increase in liver mass ratio by 26.8%, as well as an increase in this indicator in kidneys and thymus by 10.1% and 23.3%, respectively. Additional administration of hydrogen sulfide to rats eliminated the difference in weight organs and returned it to the range of statistical error.Thus, the artificially created excess of hydrogen sulfide in the body of experimental rats can reduce the acute toxicity of clindamycin phosphate.

clindamycin phosphate, hydrogen sulfide, LD50, rats, toxicity.

1. Klein EY, Van Boeckel TP, Martinez EM, Pant S, Gandra S, Levin SA, et al. Global increase and geographic convergence in antibiotic consumption between 2000 and 2015. Proc Natl Acad Scien USA. 2018 Apr 10;115(15):3463-3470. doi: 10.1073/pnas.1717295115.
2. Cassini A, Högberg LD, Plachouras D, Quattrocchi A, Hoxha A, Simonsen GS, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019 Jan;19(1):56-66. doi: 10.1016/S1473-3099(18)30605-4.
3. Voloshchuk N, Taran I, Pashynska O, Melnyk A, Magdebura S. The role of hydrogen sulfide in gastrointestinal tract functioning (review). Current Issues in Pharmacy and Medical Sciences. 2020;33(1):45-50. doi: https://doi.org/10.2478/cipms-2020-0009.
4. Kimura H. Hydrogen sulfide: its production, release and functions. Amino Acids. 2011 Jun;41(1):113-21. doi: 10.1007/s00726-010-0510-x..
5. Cai H, Wang X. Effect of sulfur dioxide on vascular biology. Histol Histopathol. 2020 Dec 15;18290:1-29. doi: 10.14670/HH-18-290.
6. Whiteman M, Le Trionnaire S, Chopra M, Fox B, Whatmore J. Emerging role of hydrogen sulfide in health and disease: critical appraisal of biomarkers and pharmacological tools. Clin Sci (Lond). 2011 Dec;121(11):459-88. doi: 10.1042/CS20110267.
7. Xiao Q, Ying J, Xiang L, Zhang C. The biologic effect of hydrogen sulfide and its function in various diseases. Medicine (Baltimore). 2018 Nov;97(44):e13065. doi: 10.1097/MD.0000000000013065.
8. Bhatia M, Wong FL, Fu D, Lau HY, Moochhala SM, Moore PK. Role of hydrogen sulfide in acute pancreatitis and associated lung injury. FASEB J. 2005 Apr;19(6):623-5. doi: 10.1096/fj.04-3023fje.
9. Voloshchuk NI, Taran IV. Hostra toksychnist hidrohen sulfidu ta yoho vplyv na protyzapalnyi efekt dyklofenaku v eksperymenti. Medychna khimiia [Internet]. 2013;13(4):88-90. Available from: https://ojs.tdmu.edu.ua/index. php/med-chem/article/view/385. [in Ukrainian].
10. Smieja M. Current indications for the use of clindamycin: A critical review. Can J Infect Dis. 1998 Jan;9(1):22-8. doi: 10.1155/1998/538090.
11. Murphy PB, Bistas KG, Le JK. StatPearls Clindamycin [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 [Updated 2020 Jun 28]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK519574/.
12. Stefanov O. Doklinichni doslidzhennia likarskykh zasobiv: metodychni rekomendatsii. Kyiv: Avitsena; 2001. 528 s. [in Ukrainian].
13. Voloshchuk NI, Taran IV, Melnik AV. Vascular mechanism in the formation of diclophenac induced gastrotoxicity: the association with the level of hydrogen sulfide. Curierul medical. 2015 Feb;58(1):7-11.
14. Karbovskyi VL, Shevchuk IA, Kurkina OV, Makovska TY. Doslidzhennia hostroi toksychnosti preparatu Heksiia. Farmatsevtychnyi zhurnal. 2016;6:88-94.[in Ukrainian].
15. Pastushenko TV, Marushyn LB, Zhukov AA, Pylypenko YuA. Ekspres-metod opredelenyia srednesmertelnikh doz veshchestv. Hyhyena y sanytaryia. 1985;6:46-48. [in Ukrainian].
16. Sidorov KK. O klassifikatsii toksichnosti yadov pri parenteralnyih sposobah vvedeniya. Toksikologiya novyih prom. veschestv. 1973;13:45- 71. [in Russian].
17. McEvoy G, Snow E. AHFS drug information 2018. Bethesda, MD: American Society of Health System Pharmacists; 2018. 3824 p.
18. Gray JE, Weaver RN, Bollert JA, Feenstra ES. The oral toxicity of clindamycin in laboratory animals. Toxicol Appl Pharmacol. 1972 Apr;21(4):516-31. doi: 10.1016/0041-008x(72)90008-7.
19. Frankel RI. Clindamycin–efficacy and toxicity. West J Med. 1975 Jun;122(6):526-30. 20.McMaster OG. Cleocin. Review of pharmacological and toxicological data. 1999 Aug;1:5.

«Bulletin of problems biology and medicine» Issue 2 (160), 2021 year, 132-135 pages, index UDK 577.18+546.221.1+615.099.092

10.29254/2077-4214-2021-2-160-132-135